B-ALL – Medxy AI

$Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin$

Prognostic Factors and Role of Allo-HSCT in First Salvage Therapy for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Blinatumomab and Inotuzumab Ozogamicin

By MedXY 09/20/2026

Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin. Allogeneic stem cell transplantation (allo-HSCT) benefits select high-risk patients.

Hematology-Oncology news

Discovery of a Novel B-ALL Subtype Defined by IGH::FENDRR Rearrangement and KRAS Mutations With Poor Chemotherapy Response

By MedXY 08/27/2026

A novel B-cell acute lymphoblastic leukemia subtype characterized by IGH::FENDRR rearrangement and KRAS mutations shows distinct molecular features and poor response to standard chemotherapy, highlighting the need for early immunotherapy and targeted interventions.

$Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL$

Hematology-Oncology news Oncology

Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL

By MedXY 06/06/2026

A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.

Hematology-Oncology news

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

By MedXY 06/02/2026

A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Self-Reinforcing IL-1β Signaling Accelerates TCF3::HLF-Positive B-ALL Development and Relapse

By MedXY 05/27/2026

Researchers found that IL-1β signaling drives growth, relapse, and bone damage in TCF3::HLF-positive B-ALL, suggesting IL-1β blockade may offer a new treatment strategy.

Hematology-Oncology news

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

By MedXY 11/24/2025

A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activity. Larger controlled studies are needed to confirm benefit and infectious risk.

Hematology-Oncology Specialties

Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL

By MedXY 08/29/2025

Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.